Rosuvastatin Reduces Blood Viscosity in Patients with Acute Coronary Syndrome

Lae-Young Jung1, Sang-Rok Lee1, Jin-Mu Jung2

  • 1Division of Cardiology, Chonbuk National University Hospital and Chonbuk National University Medical School, Jeonju, Korea.

Insights

Statins significantly reduce whole blood viscosity (WBV) in acute coronary syndrome (ACS) patients. One month of rosuvastatin treatment lowered WBV in statin-naïve individuals, indicating statins

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Biophysics

Background:

  • Wall shear stress is implicated in atherosclerosis progression and plaque rupture.
  • Limited research exists on statins' impact on whole blood viscosity (WBV) in acute coronary syndrome (ACS) patients.
  • This study investigates the effect of statin therapy on WBV in ACS patients.

Purpose of the Study:

  • To determine the effect of statin therapy on whole blood viscosity (WBV) in patients with acute coronary syndrome (ACS).
  • To compare WBV between patients with prior statin use and statin-naïve patients.
  • To assess the change in WBV after one month of rosuvastatin treatment in statin-naïve ACS patients.

Main Methods:

  • Prospective enrollment of 189 ACS patients (52 STEMI, 84 NSTEMI, 53 UA).
  • Patients divided into two groups: prior statin users (n=51) and statin-naïve (n=138).
  • Measurement of systolic (SBV) and diastolic blood viscosity (DBV) at baseline and one month post-treatment with rosuvastatin (16.2±4.9 mg/day).

Main Results:

  • Baseline WBV (SBV and DBV) was significantly higher in statin-naïve patients compared to prior statin users (p<0.003).
  • One month of rosuvastatin treatment significantly decreased WBV (SBV and DBV) in statin-naïve patients (p<0.044).
  • Low-density lipoprotein cholesterol levels showed no association with WBV at baseline or follow-up.

Conclusions:

  • Prior statin medication is a significant factor in reducing WBV in ACS patients.
  • Short-term rosuvastatin treatment effectively decreases WBV in statin-naïve ACS patients.
  • Statin therapy demonstrates a beneficial effect on hemorheological properties in ACS.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
576
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
398
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.8K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
837
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
793